CRX 527 是一种 TLR4 激动剂,可激活 TLR4 下游的 MyD88 依赖性、TRIF 依赖性以及 TRAF6/NF-κB 信号通路,模拟脂质 A,调节树突状细胞的抗原加工与提呈,刺激固有免疫应答并增强疫苗效力,同时维持造血组织、脾脏和肠道的结构完整性,减轻辐射诱导的损伤,维持肠道稳态,抑制细胞凋亡 (apoptosis)、炎症反应、氧化应激和 DNA 损伤,可用于急性放射综合征、黑色素瘤、HPV 相关肿瘤以及脑出血的研究。
产品编号: MS-F57441 CAS No.: 216014-14-1 分子式: C81H151N2O19P 分子量: 1488.04
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

CRX 527 是一种 TLR4 激动剂,可激活 TLR4 下游的 MyD88 依赖性、TRIF 依赖性以及 TRAF6/NF-κB 信号通路,模拟脂质 A,调节树突状细胞的抗原加工与提呈,刺激固有免疫应答并增强疫苗效力,同时维持造血组织、脾脏和肠道的结构完整性,减轻辐射诱导的损伤,维持肠道稳态,抑制细胞凋亡 (apoptosis)、炎症反应、氧化应激和 DNA 损伤,可用于急性放射综合征、黑色素瘤、HPV 相关肿瘤以及脑出血的研究。

生物实验数据

生物活性 CRX 527 is a TLR4 agonist that activates MyD88-dependent, TRIF-dependent, and TRAF6/NF-κB signaling pathways downstream of TLR4, mimics lipid A, modulates antigen processing and presentation in dendritic cells, stimulates innate immune responses, and enhances vaccine efficacy, while maintaining the structural integrity of hematopoietic tissue, spleen, and intestine, mitigating radiation-induced injury, preserving intestinal homeostasis, and inhibiting apoptosis, inflammatory responses, oxidative stress, and DNA damage, and can be used for research on acute radiation syndrome, melanoma, HPV-related tumors, and intracerebral hemorrhage.
体外研究
(In Vitro)

CRX 527 (1-100 ng/mL; 24 h) 可在体外上调牛外周血 γδ T 细胞上的 IL-2R 表达,其中 100 ng/mL 时的应答最强。
CRX 527 (12 h) 可激活小鼠 RAW264.7 和人 THP-1 巨噬细胞,通过减少细胞凋亡、炎症反应及 ROS 生成,保护小鼠 MODE-K 和人 HIEC 肠上皮细胞免受电离辐射诱导的损伤。
CRX 527 (2-12 h) 可激活小鼠 RAW264.7 巨噬细胞中的 TLR4-MyD88 和 TLR4-TRIF 信号通路。
CRX 527 (0.04-500 nM; 24 h) 与 OVA CTL 或 OVA 辅助肽偶联后仍保留 TLR4 激活活性,可诱导 D1 树突状细胞产生 IL-12p40,其效力与游离 CRX-527 相近。
CRX 527 (427-3500 nM; 过夜) 与 OVA CTL 肽偶联后可增强 D1 树突状细胞对 SIINFEKL 表位的 MHC I 类抗原呈递作用,其诱导 B3Z 报告 T 细胞活化的强度高于游离肽或 CRX-527-肽混合物。
CRX 527 (78.1-5000 nM; 过夜) 与 OVA 辅助肽偶联后,可增强 D1 树突状细胞对 OVA 辅助性 T 细胞表位的 MHC II 类抗原呈递作用,其诱导 OTIIZ 报告基因 T 细胞活化的强度高于游离肽或 CRX-527-肽混合物。
CRX 527 (7.8-500 nM; 50 h) 与 OVA CTL 肽偶联后,可增强与经脉冲处理的 D1 树突状细胞共培养的初始 OT-I CD8+ T 细胞的活化及多功能细胞因子 (IFNγ 和 TNFα) 的产生,其效力优于游离肽或 CRX-527-肽混合物。
CRX 527 (31-2000 nM; 50 h) 与 OVA 辅助肽偶联后,可增强经脉冲处理的 D1 树突状细胞共培养的初始 OT-II CD4+ T 细胞的活化及多功能细胞因子 (IFNγ 和 TNFα) 的产生,其效力优于游离肽或 CRX-527-肽混合物。
CRX 527 (78.1-5000 nM; 50 h) 与 EnvH 肽偶联后,可增强 D1 树突状细胞对 EnvH 表位的 MHC II 类抗原呈递,相较于游离肽或 CRX-527-肽混合物,其能诱导 3A12 报告基因 T 细胞更强的活化,并诱导初始 MolH CD4+ T 细胞产生 TNFα。

ELISA Assay

Cell Line: mouse spleen-derived immature D1 DC cell line
Concentration: 0.04, 0.2, 1, 5, 20, 500 nM
Incubation Time: 24 h
Result: Induced IL-12p40 production in D1 DCs in a concentration-dependent manner, with levels comparable to free CRX-527.
Induced ~7 ng/mL IL-12p40 at 500 nM when conjugated to OVA CTL peptide.
Induced ~7 ng/mL IL-12p40 at 500 nM when conjugated to OVA Help peptide.
Induced ~8 ng/mL IL-12p40 at 500 nM in free form.
体内研究
(In Vivo)

CRX 527 (1 μg;经气管给药;单次给药) 在健康 C57BL/6 小鼠中诱导的肺中性粒细胞募集作用比 lipo-CRX、LPS 或 MPL 更强,且对血液中性粒细胞或巨噬细胞的百分比无影响。
CRX 527 (0.5 mg/kg;腹腔注射;2 次) 可使接受 7.5 Gy 全身照射的 C57BL/6 小鼠存活率达到 100%,同时有效缓解电离辐射诱导的造血系统损伤。
CRX 527 (0.5 mg/kg;腹腔注射;2 次) 可在 C57BL/6 小鼠中激活造血动员以及造血干细胞向免疫有利方向的分化,提升 LSK 和 GMP 细胞群数量同时减少具有免疫抑制作用的 MDSCs。
CRX 527 (0.5 mg/kg;腹腔注射;2 次) 可提高经 5Gy 全身照射的 C57BL/6 小鼠的骨髓巨噬细胞比例,维持其外周血白细胞计数,并激活巨噬细胞介导的免疫防御。
CRX 527 (0.5 mg/kg;腹腔注射;2 次) 可使接受 9 Gy 局部腹部照射的 C57BL/6 小鼠存活率达到 80%,同时保护肠道稳态、干细胞再生及屏障功能免受电离辐射损伤。
CRX 527 (0.5 mg/kg;腹腔注射;2 次) 无法在 TLR4 基因敲除小鼠中抵御电离辐射诱导的造血系统或肠道损伤,表明其辐射防护作用是通过激活 TLR4 介导的。
CRX 527 (2 nmol;皮内注射;2 次 (第 0 天、第 14 天))-肽偶联物,尤其是 CTL + T 辅助细胞联合偶联物,经预防性接种后可诱导强烈的肿瘤特异性 CD8 T 细胞应答,并使接种 B16OVA 黑色素瘤的小鼠获得约 90% 的长期存活率。

Animal Model: C57BL/6 (6- to 10-week-old, mixed male and female, approximately equal numbers, 5 mice per group)
Dosage: 1 μg
Administration: i.t.; single dose
Result: Induced a more robust lung neutrophil influx than lipo-CRX, LPS, or MPL.
Did not alter blood neutrophil or macrophage percentages at 24 hours post-treatment.
Animal Model: C57BL/6 (weight 18-20 g; total body irradiation with 7.5 Gy X-ray)
Dosage: 0.5 mg/kg
Administration: i.p.; twice (24 hours and 2 hours pre-irradiation)
Result: Increased post-irradiation survival rate to 100% (compared to 50% in untreated irradiated mice).
Showed more gradual weight changes, preserved higher bone marrow nucleated cell counts, higher spleen coefficients, greater numbers of LSK (lin-sca-1+ c-kit+) cells, more intact bone marrow hematopoietic microenvironment with fewer vacuoles, more complete blood sinus structure, and higher spleen white pulp cell density relative to untreated irradiated mice.
Animal Model: C57BL/6
Dosage: 0.5 mg/kg
Administration: i.p.; twice (24 hours and 2 hours prior to sample collection)
Result: Increased the proportion and number of LSK (Lin-sca-1+ c-kit+) cells.
Reduced the proportion of long-term hematopoietic stem cells (LT-HSCs, CD34- CD135- LSK) and increased the proportion of short-term hematopoietic stem cells (ST-HSCs, CD34+ CD135- LSK) and multipotent hematopoietic progenitors (MPPs, CD34+ CD135+ LSK).
Promoted differentiation of hematopoietic progenitor cells (HPCs) into granulocyte/monocyte progenitor cells (GMPs, FcRhighCD34+ LK).
Decreased the proportion of bone marrow-derived inhibitory cells (MDSCs, CD45+ Gr-1+ CD11b+).
Animal Model: C57BL/6 (total body irradiation with 5 Gy X-ray)
Dosage: 0.5 mg/kg
Administration: i.p.; twice (24 hours and 2 hours pre-irradiation)
Result: Maintained higher peripheral blood white blood cell counts throughout the observation period post-irradiation.
Increased the proportion of bone marrow macrophages (CD11b+ F4/80+) relative to untreated irradiated mice.
Animal Model: C57BL/6 (local abdominal irradiation with 9 Gy X-ray)
Dosage: 0.5 mg/kg
Administration: i.p.; twice (24 hours and 2 hours pre-irradiation)
Result: Increased post-irradiation survival rate to 80% (compared to 0% in untreated irradiated mice).
Showed more gradual weight changes, preserved intestinal crypt-villus structure, maintained higher counts of Lgr5+ intestinal stem cells, Lysozyme+ Paneth cells, and Ki67+ epithelial regeneration cells, more complete villin expression, higher fecal quantity and weight without watery/loose stools, retained higher ZO-1 expression to preserve intestinal barrier function, suppressed 8-OHdG oxidative stress marker levels, and reduced intestinal tissue expression of PARP, IL-1β, IL-6, TNF-α, and Caspase-3 relative to untreated irradiated mice.
Animal Model: TLR4 knockout (TLR4-/-) (total body irradiation with 7.5 Gy and 5 Gy X-ray)
Dosage: 0.5 mg/kg
Administration: i.p.; twice (24 hours and 2 hours pre-irradiation)
Result: Had no significant effect on post-irradiation survival rate, body weight changes, spleen coefficient, bone marrow nucleated cell counts, spleen nucleated cell counts, peripheral blood white blood cell counts, LSK cell proportions, GMP cell proportions, MDSC cell proportions, bone marrow macrophage proportions, intestinal F4/80 macrophage levels, or intestinal crypt counts in irradiated TLR4-/- mice relative to untreated irradiated TLR4-/- mice.
Animal Model: Sprague-Dawley (SD) (220-250 g)
Dosage: 0.25 mg/kg
Administration: i.p.; single dose (before ICH injury)
Result: Reversed the NR4A2-mediated reduction in BBB permeability by increasing FITC-dextran penetration, perivascular IgG accumulation, and Evans blue extravasation in ICH rats.
Reversed the NR4A2-mediated suppression of ICH-induced increases in P-selectin, ICAM-1, CXCL1, and CCL2 mRNA levels in perihematomal tissues.
Counteracted the NR4A2-driven shift toward M2 microglial polarization by increasing levels of M1 markers (iNOS, CD86) and decreasing levels of M2 markers (CD206, Arg-1) in perihematomal tissues.
Reversed the NR4A2-mediated suppression of the TLR4/TRAF6/NF-κB pathway, increasing protein levels of TLR4, TRAF6, and p-NF-κB p65.
Exacerbated ICH-induced BBB disruption, increased inflammatory marker expression, promoted M1 microglial polarization, and enhanced activation of the TLR4/TRAF6/NF-κB pathway when administered alone.

化学信息

分子量 1488.04
分子式 C81H151N2O19P
CAS No. 216014-14-1

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础